FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market

The FDA approval of Eli Lilly’s oral GLP-1 "Foundayo" represents a high-conviction catalyst that structurally pivots the competitive landscape, potentially forcing a reversal in the recent oversold technical exhaustion observed in LLY. With an RSI of 22.97, LLY is significantly technically oversold despite robust fundamental catalysts, suggesting the stock is primed for a mean-reversion move; the news acts as the necessary volume trigger to close the technical gap created by the recent bearish sentiment surrounding NHS pricing disputes. While NVO remains in a neutral state, LLY’s strategic expansion into oral delivery addresses a major bottleneck in patient adherence identified in their recent 10-K, providing a clear path to capture market share from the current injection-only paradigm. Traders should look for a breakout above the $950 resistance level, supported by the bullish MACD crossover, to confirm a trend reversal, while keeping a tight stop-loss below the $910 support to mitigate risks associated with the ongoing pricing rhetoric in the UK. This confluence of a "bottom-of-range" RSI bounce and a disruptive product launch suggests an asymmetric risk-reward profile for long positions, provided volume sustains above the 1.2x average threshold.